STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

Why sleep matters when it comes to weight gain and loss

STAT+: With Stephen Miller as chief of staff, Kennedy’s MAHA agenda is reinvigorated
